{"id":"W3138496492","doi":"10.1182/bloodadvances.2020003510","title":"Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"Pharmacyclics; Genentech; Astellas Pharma; Incyte; Agios Pharmaceuticals; Jazz Pharmaceuticals; Amgen; Ariad Pharmaceuticals; Kaiser Permanente; University of Rochester; Teva Pharmaceutical Industries; Kite Pharma; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Medicine; Hazard ratio; Internal medicine; Confidence interval; Transplantation; Cytarabine; Clinical endpoint; Neutropenia; Post-hoc analysis; Gastroenterology; Myeloid leukemia; Surgery; Oncology; Chemotherapy; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005095371,0.001143581,0.002759454,0.0003407579,0.0004353487,0.0009797707,0.0007867443,0.000963805,0.003079255],"category_scores_gemma":[0.004756658,0.000358365,0.005282301,0.0004738721,0.0004480341,0.0009999326,0.0006291026,0.001834676,0.0003850049],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006263646,"about_ca_system_score_gemma":0.001320694,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001098838,"about_ca_topic_score_gemma":0.002081009,"domain_scores_codex":[0.9977669,0.001167005,0.0001555443,0.0003604123,0.0002089304,0.0003411442],"domain_scores_gemma":[0.9961998,0.001823839,0.0007108282,0.0004742257,0.0002999396,0.0004912307],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9330524,0.006963606,0.03372978,0.0003756896,0.007020971,0.0001515138,0.0001707396,0.001571454,0.003197933,0.0001151592,0.001273441,0.01237731],"study_design_scores_gemma":[0.189919,0.4581852,0.3177568,0.00007061661,0.01825735,0.0002700981,0.0003950611,0.005760598,0.003888352,0.0006272412,0.004754021,0.0001157023],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954712,0.0005926792,0.0004018685,0.0001026706,0.00005756489,0.001191675,0.001419881,0.00001935138,0.0007431402],"genre_scores_gemma":[0.9910781,0.0003698095,0.001091031,0.0004295083,0.0001544665,0.002990047,0.002760047,0.00002100942,0.001106059],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005095371,"threshold_uncertainty_score":0.02694726,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01120123864404248,"score_gpt":0.3122672634061165,"score_spread":0.3010660247620741,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}